Wall Street Zen upgraded shares of Tactile Systems Technology (NASDAQ:TCMD – Free Report) from a buy rating to a strong-buy rating in a research note published on Saturday.
Other research analysts have also issued reports about the company. B. Riley restated a “neutral” rating and set a $13.00 price target (up from $12.00) on shares of Tactile Systems Technology in a research report on Tuesday, August 5th. Lake Street Capital initiated coverage on Tactile Systems Technology in a research report on Friday, October 3rd. They set a “buy” rating and a $23.50 price target for the company. Weiss Ratings reiterated a “hold (c)” rating on shares of Tactile Systems Technology in a report on Wednesday, October 8th. Finally, William Blair upgraded Tactile Systems Technology to a “strong-buy” rating in a report on Tuesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $16.83.
Read Our Latest Stock Report on Tactile Systems Technology
Tactile Systems Technology Trading Up 4.6%
Tactile Systems Technology (NASDAQ:TCMD – Get Free Report) last released its quarterly earnings results on Monday, November 3rd. The company reported $0.36 EPS for the quarter, topping the consensus estimate of $0.16 by $0.20. Tactile Systems Technology had a return on equity of 7.72% and a net margin of 5.06%. Tactile Systems Technology has set its FY 2025 guidance at EPS. As a group, research analysts predict that Tactile Systems Technology will post 0.7 earnings per share for the current year.
Insider Transactions at Tactile Systems Technology
In other Tactile Systems Technology news, CEO Sheri Louise Dodd sold 7,762 shares of Tactile Systems Technology stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $12.36, for a total transaction of $95,938.32. Following the completion of the sale, the chief executive officer directly owned 173,479 shares of the company’s stock, valued at $2,144,200.44. The trade was a 4.28% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 2.50% of the stock is owned by company insiders.
Institutional Trading of Tactile Systems Technology
Institutional investors have recently bought and sold shares of the business. Dynamic Technology Lab Private Ltd purchased a new stake in Tactile Systems Technology during the 1st quarter worth about $534,000. Victory Capital Management Inc. purchased a new stake in Tactile Systems Technology during the 1st quarter worth about $1,160,000. Acadian Asset Management LLC grew its holdings in shares of Tactile Systems Technology by 149.1% during the first quarter. Acadian Asset Management LLC now owns 196,270 shares of the company’s stock worth $2,594,000 after purchasing an additional 117,480 shares during the last quarter. Punch & Associates Investment Management Inc. grew its holdings in shares of Tactile Systems Technology by 34.3% during the first quarter. Punch & Associates Investment Management Inc. now owns 282,000 shares of the company’s stock worth $3,728,000 after purchasing an additional 72,000 shares during the last quarter. Finally, Invesco Ltd. increased its position in shares of Tactile Systems Technology by 19.8% during the first quarter. Invesco Ltd. now owns 35,637 shares of the company’s stock worth $471,000 after purchasing an additional 5,879 shares in the last quarter. 83.43% of the stock is owned by hedge funds and other institutional investors.
Tactile Systems Technology Company Profile
Tactile Systems Technology, Inc, a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema in the home setting; and Entre Plus System, a portable pneumatic compression device for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers.
Featured Articles
- Five stocks we like better than Tactile Systems Technology
- What Are Growth Stocks and Investing in Them
- Semiconductor Supercycle: Why Onsemi Stock Could Double as AI and EV Growth Accelerate
- What Is WallStreetBets and What Stocks Are They Targeting?
- The Best Local Butchers for Thanksgiving [2025 Survey]
- 3 Warren Buffett Stocks to Buy Now
- $134M in Insider Moves: What It Might Mean for KMI, ISRG and QS
Receive News & Ratings for Tactile Systems Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tactile Systems Technology and related companies with MarketBeat.com's FREE daily email newsletter.
